1
|
Sun J, Cheng M, Ye T, Li B, Wei Y, Zheng H, Zheng H, Zhou M, Piao JG, Li F. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy. Nanomedicine (Lond) 2022; 17:2037-2054. [PMID: 36789952 DOI: 10.2217/nnm-2022-0250] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
Hepatocellular carcinoma (HCC) poses a severe threat to human health and economic development. Despite many attempts at HCC treatment, most are inevitably affected by the genetic instability and variability of tumor cells. Arsenic trioxide (ATO) has shown to be effective in HCC. However, time-consuming challenges, especially the optimal concentration in tumor tissue and bioavailability of ATO, remain to be overcome for its transition from the bench to the bedside. To bypass these issues, nanotechnology-based delivery systems have been developed for prevention, diagnosis, monitoring and treatment in recent years. This article is a systematic overview of the latest contributions and detailed insights into ATO-loaded nanocarriers, with particular attention paid to strategies for improving the efficacy of nanocarriers of ATO.
Collapse
Affiliation(s)
- Jiang Sun
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Mengying Cheng
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Tingxian Ye
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Bin Li
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Yinghui Wei
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Hangsheng Zheng
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Hongyue Zheng
- Libraries of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Meiqi Zhou
- Department of Oncology Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
| | - Ji-Gang Piao
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
- Key Laboratory of Neuropharmacology & Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
- Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Fanzhu Li
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
- Key Laboratory of Neuropharmacology & Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| |
Collapse
|
2
|
Mourtas S, Papadia K, Kordopati GG, Ioannou PV, Antimisiaris SG, Tsivgoulis GM. Synthesis of Novel Arsonolipids and Development of Novel Arsonoliposome Types. Pharmaceutics 2022; 14:pharmaceutics14081649. [PMID: 36015274 PMCID: PMC9416600 DOI: 10.3390/pharmaceutics14081649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 07/29/2022] [Accepted: 08/05/2022] [Indexed: 11/16/2022] Open
Abstract
Arsonolipids represent a class of arsenic-containing compounds with interesting biological properties either as monomers or as nanostructure forming components, such as arsonoliposomes that possess selective anticancer activity as proven by in vitro and in vivo studies. In this work, we describe, for the first time, the synthesis of novel arsono-containing lipids where the alkyl groups are connected through stable ether bonds. It is expected that this class of arsonolipids, compared with the corresponding ester linked, will have higher chemical stability. To accomplish this task, a new methodology of general application was developed, where a small arsono compound, 2-hydroxyethylarsonic acid, when protected with thiophenol, can be used in an efficient and simple way as a building block for the synthesis of arsono-containing lipids as well as other arsono-containing biomolecules. Thus, besides the above-mentioned arsonolipid, an arsono cholesterol derivative was also obtained. Both ether arsonolipid and arsono cholesterol were able to form liposomes having similar physicochemical properties and integrity to conventional arsonoliposomes. Furthermore, a preliminary in vitro anticancer potential assessment of the novel ether arsonolipid containing liposomes against human prostate cancer (PC-3) and Lewis lung carcinoma (LLC) cells showed significant activity (dose- and time-dependent), which was similar to that of the conventional arsonoliposomes (studied before). Given the fact that novel arsonolipids may be more stable compared to the ones used in conventional arsonoliposomes, the current results justify further exploitation of the novel compounds by in vitro and in vivo studies.
Collapse
Affiliation(s)
- Spyridon Mourtas
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26510 Rio Patras, Greece
- Department of Chemistry, University of Patras, 26510 Rio Patras, Greece
- Correspondence: (S.M.); (G.M.T.)
| | - Konstantina Papadia
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26510 Rio Patras, Greece
| | | | | | - Sophia G. Antimisiaris
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26510 Rio Patras, Greece
- Institute of Chemical Engineering Sciences, Foundation for Research and Technology Hellas (FORTH/ICES), 26504 Rio Patras, Greece
| | - Gerasimos M. Tsivgoulis
- Department of Chemistry, University of Patras, 26510 Rio Patras, Greece
- Correspondence: (S.M.); (G.M.T.)
| |
Collapse
|
3
|
Liposomal formulation of new arsenic schiff base complex as drug delivery agent in the treatment of acute promyelocytic leukemia and quantum chemical and docking calculations. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
4
|
Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Med Res Rev 2021; 42:374-398. [PMID: 34309879 DOI: 10.1002/med.21844] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 06/18/2021] [Accepted: 07/04/2021] [Indexed: 12/18/2022]
Abstract
Despite having a rich history as a poison, arsenic and its compounds have also gained a great reputation as promising anticancer drugs. As a pioneer, arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia. Many in vitro studies suggested that arsenic trioxide could also be used in the treatment of solid tumors. However, the transition from bench to bedside turned out to be challenging, especially in terms of the drug bioavailability and concentration reaching tumor tissues. To address these issues, nanomedicine tools have been proposed. As nanocarriers of arsenic trioxide, various materials have been examined including liposomes, polymer, and inorganic nanoparticles, and many other materials. This review gives an overview of the existing strategies of delivery of arsenic trioxide in cancer treatment with a focus on the drug encapsulation approaches and medicinal impact in the treatment of solid tumors. It focuses on the progress in the last years and gives an outlook and suggestions for further improvements including theragnostic approaches and targeted delivery.
Collapse
Affiliation(s)
- Marthe Sönksen
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
| | - Kornelius Kerl
- Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
| | - Hana Bunzen
- Chair of Solid State and Materials Chemistry, Institute of Physics, University of Augsburg, Augsburg, Germany
| |
Collapse
|
5
|
Zagana P, Mourtas S, Basta A, Antimisiaris SG. Preparation, Physicochemical Properties, and In Vitro Toxicity towards Cancer Cells of Novel Types of Arsonoliposomes. Pharmaceutics 2020; 12:E327. [PMID: 32268585 PMCID: PMC7238025 DOI: 10.3390/pharmaceutics12040327] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 03/30/2020] [Accepted: 04/01/2020] [Indexed: 12/23/2022] Open
Abstract
Arsonoliposomes (ARSL) are liposomes that incorporate arsonolipids (ARS) in their membranes. They have demonstrated significant toxicity towards cancer cells, while being less toxic towards normal cells. In this study, we sought to investigate the possibility to prepare novel types of arsonoliposomes (ARSL) by incorporating a lipidic derivative of curcumin (TREG) in their membrane, and/or by loading the vesicles with doxorubicin (DOX). The final aim of our studies is to develop novel types of ARSL with improved pharmacokinetics/targeting potential and anticancer activity. TREG was incorporated in ARSL and their integrity during incubation in buffer and serum proteins was studied by monitoring calcein latency. After evaluation of TREG-ARSL stability, the potential to load DOX into ARSL and TREG-ARSL, using the active loading protocol, was studied. Loading was performed at two temperatures (40 °C and 60 °C) and different time periods of co-incubation (of empty vesicles with DOX). Calculation of DOX entrapment efficiency (%) was based on initial and final drug/lipid ratios. The cytotoxic activity of DOX-ARSL was tested towards B16F10 cells (mouse melanoma cells), LLC (Lewis Lung carcinoma cells), and HEK-293 (Human embryonic kidney cells). Results show that TREG-ARSL have slightly larger size but similar surface charge with ARSL and that they are both highly stable during storage at 4 °C for 56 d. Interestingly, the inclusion of TREG in ARSL conferred increased stability to the vesicles towards disruptive effects of serum proteins. The active-loading protocol succeeded to encapsulate high amounts of DOX into ARSL as well as TREG-LIP and TREG-ARSL, while the release profile of DOX from the novel liposome types was similar to that demonstrated by DOX-LIP. The cytotoxicity study results are particularly encouraging, since DOX-ARSL were less toxic towards the (normal) HEK cells compared to the two cancer cell-types. Furthermore, DOX-ARSL demonstrated lower toxicities (at all concentrations tested) for HEK cells, compared to that of the corresponding mixtures of free DOX and empty ARSL, while the opposite was true for the cancer cells (in most cases). The current results justify further in vivo exploitation of DOX-ARSL, as well as TREGARSL as anticancer therapeutic systems.
Collapse
Affiliation(s)
- Paraskevi Zagana
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, 26504 Rio-Patras, Greece; (P.Z.); (S.M.); (A.B.)
| | - Spyridon Mourtas
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, 26504 Rio-Patras, Greece; (P.Z.); (S.M.); (A.B.)
- Lab. Pharm. Technology, Department of Pharmacy, University of Patras, 26504 Rio-Patras, Greece
| | - Anastasia Basta
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, 26504 Rio-Patras, Greece; (P.Z.); (S.M.); (A.B.)
- Lab. Pharm. Technology, Department of Pharmacy, University of Patras, 26504 Rio-Patras, Greece
| | - Sophia G. Antimisiaris
- Foundation for Research and Technology Hellas, Institute of Chemical Engineering Sciences, FORTH/ICE-HT, 26504 Rio-Patras, Greece; (P.Z.); (S.M.); (A.B.)
- Lab. Pharm. Technology, Department of Pharmacy, University of Patras, 26504 Rio-Patras, Greece
| |
Collapse
|
6
|
Tanaka J, Davis TP, Wilson P. Organic Arsenicals as Functional Motifs in Polymer and Biomaterials Science. Macromol Rapid Commun 2018; 39:e1800205. [PMID: 29806240 DOI: 10.1002/marc.201800205] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Revised: 04/09/2018] [Indexed: 12/29/2022]
Abstract
Arsenic (As) exhibits diverse (bio)chemical reactivity and biological activity depending upon its oxidation state. However, this distinctive reactivity has been largely overlooked across many fields owing to concerns regarding the toxicity of arsenic. Recently, a clinical renaissance in the use of arsenicals, including organic arsenicals that are known to be less toxic than inorganic arsenicals, alludes to the possibility of broader acceptance and application in the field of polymer and biomaterials science. Here, current examples of polymeric/macromolecular arsenicals are reported to stimulate interest and highlight their potential as a novel platform for functional, responsive, and bioactive materials.
Collapse
Affiliation(s)
- Joji Tanaka
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
| | - Thomas P Davis
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 399 Royal Parade, Parkville, Victoria, 3152, Australia
| | - Paul Wilson
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 399 Royal Parade, Parkville, Victoria, 3152, Australia
| |
Collapse
|
7
|
Ioannou PV. Arsonolipids, pseudo arsonolipids, arsinolipids and arsonoliposomes: Preparations, biophysical, biochemical and biological aspects. MAIN GROUP CHEMISTRY 2018. [DOI: 10.3233/mgc-180255] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
8
|
Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem 2018; 23:313-329. [DOI: 10.1007/s00775-018-1537-9] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 01/22/2018] [Indexed: 01/01/2023]
|
9
|
Akhtar A, Wang SX, Ghali L, Bell C, Wen X. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. J Biomed Res 2017; 31:177-188. [PMID: 28808212 PMCID: PMC5460606 DOI: 10.7555/jbr.31.20160059] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 08/22/2016] [Indexed: 12/26/2022] Open
Abstract
Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation. However, the clinical successes of arsenic trioxide in treating hematological cancers have not been translated to solid cancers. This is due to arsenic's rapid clearance by the body's immune system before reaching the tumor site. Several attempts have henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without much success. This review summarizes the past and current utilization of arsenic trioxide in the medical field with primary focus on the implementation of nanotechnology for arsenic trioxide delivery to solid cancer cells. Different approaches that have been employed to increase arsenic's efficacy, specificity and bioavailability to solid cancer cells were evaluated and compared. The potential of combining different approaches or tailoring delivery vehicles to target specific types of solid cancers according to individual cancer characteristics and arsenic chemistry is proposed and discussed.
Collapse
Affiliation(s)
- Anam Akhtar
- Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK
| | - Scarlet Xiaoyan Wang
- Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK
| | - Lucy Ghali
- Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK
| | - Celia Bell
- Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK
| | - Xuesong Wen
- Department of Natural Sciences, School of Science and Technology, Middlesex University, London NW4 4BT, UK
| |
Collapse
|
10
|
Al-Shehri A, Favretto ME, Ioannou PV, Romero IA, Couraud PO, Weksler BB, Parker TL, Kallinteri P. Permeability of PEGylated Immunoarsonoliposomes Through In Vitro Blood Brain Barrier-Medulloblastoma Co-culture Models for Brain Tumor Therapy. Pharm Res 2014; 32:1072-83. [DOI: 10.1007/s11095-014-1519-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2014] [Accepted: 09/12/2014] [Indexed: 10/24/2022]
|
11
|
Tanaka K, Chujo Y. Design of functionalized nanoparticles for the applications in nanobiotechnology. ADV POWDER TECHNOL 2014. [DOI: 10.1016/j.apt.2013.07.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
12
|
Ioannou PV, Tsivgoulis GM, Lala MA. Racemic 2,3,4-Triacyloxybutylarsonic Acids: A New Class of Arsonolipids with Three Acyl Chains. PHOSPHORUS SULFUR 2013. [DOI: 10.1080/10426507.2012.727512] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
| | | | - Maria A. Lala
- a Department of Chemistry , University of Patras , Patras , Greece
| |
Collapse
|
13
|
Fu M, Qin C, Li W, Yan Y, Zeng L, Yang X. Effect of glucosamine and chitooligomer on the toxicity of arsenite against Escherichia coli. Carbohydr Polym 2012; 91:390-3. [PMID: 23044148 DOI: 10.1016/j.carbpol.2012.08.065] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2012] [Revised: 08/17/2012] [Accepted: 08/19/2012] [Indexed: 10/28/2022]
Abstract
Escherichia coli was selected as the sample to study the toxicity of arsenite in the presence of saccharides. The effect of glucosamine, N-acetylglucosamine, glucose, lactose, sucrose, glucosamine and cyclodextrin on the toxicity of arsenite against E. coli was investigated by microcalorimetry. The glucosamine and the tested chitooligomer decreased the toxicity of arsenite on cells of E. coli, and the effect of glucosamine was stronger than that of the chitooligomer. These results suggest that the glucosamine and chitooligomer may be employed as the assistant antidote for arsenite.
Collapse
Affiliation(s)
- Meifang Fu
- Hubei Key Laboratory of Biomass-Resource Chemistry and Environmental Biotechnology, Hubei Engineering University, Xiaogan 432000, China
| | | | | | | | | | | |
Collapse
|
14
|
Minehara H, Narita A, Naka K, Tanaka K, Chujo M, Nagao M, Chujo Y. Tumor cell-specific prodrugs using arsonic acid-presenting iron oxide nanoparticles with high sensitivity. Bioorg Med Chem 2012; 20:4675-9. [DOI: 10.1016/j.bmc.2012.06.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 06/06/2012] [Accepted: 06/06/2012] [Indexed: 10/28/2022]
|
15
|
Ioannou PV, Afroudakis PA, Siskos MG. Preparation of 2-Picolylarsonic Acid and its Reductive Cleavage by Ascorbic Acid/Iodine and by Thiophenol. PHOSPHORUS SULFUR 2010. [DOI: 10.1080/10426500214875] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Antimisiaris SG, Ioannou PV. Arsonoliposomes: preparation and physicochemical characterization. Methods Mol Biol 2010; 605:147-62. [PMID: 20072879 DOI: 10.1007/978-1-60327-360-2_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Arsonoliposomes (ARSL) which are liposomes that contain arsonolipids in their membranes have shown interesting anticancer and antiparasitic activity in vitro. Their lipid composition (the specific arsonolipids and/or phospholipids used for their preparation, and the relative amounts of each lipid type) highly influences their physicochemical properties as well as their in vivo kinetics and antiparasitic activity; however, their cytotoxicity towards cancer cells is minimally--if at all--modified. ARSL are prepared by a modification of the "one step" method followed or not by sonication (for formation of sonicated or non-sonicated ARSL, respectively). Arsonoliposomes may be composed only of arsonolipids (containing or not cholesterol) [plain ARSL], or they may contain mixtures of arsonolipids with phospholipids (with or without Chol) [mixed ARSL]. Herein, we describe in detail the preparation and physicochemical characterization of ARSL.
Collapse
Affiliation(s)
- Sophia G Antimisiaris
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, and FORTH-Institute of Chemical Engineering, Patras, Greece
| | | |
Collapse
|
17
|
A high yield procedure for the preparation of arsonolipids (2,3-diacyloxypropylarsonic acids). Chem Phys Lipids 2009; 163:51-5. [PMID: 19900427 DOI: 10.1016/j.chemphyslip.2009.10.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Revised: 10/02/2009] [Accepted: 10/26/2009] [Indexed: 11/22/2022]
Abstract
The crucial step in the preparation of the title arsonolipids starting from the dichloromethane-soluble dithioarsonite CH(2)(OH)CH(OH)CH(2)-As(SPh)(2) is to avoid an internal cyclization during the acylation which protects the primary -OH group from being acylated. This was to a large extent accomplished by using fatty acyl chloride in the presence of the weak base pyridine and controlling the temperature and rate of the acyl chloride addition, giving approximately 70% yields of arsonolipids. The presence of catalytic amounts of 4-dimethylaminopyridine boosted the yields to 82-85%. This yield is a great improvement over the yields (20-55%) previously achieved. The acylating systems (RCO)(2)O or RCOCl and BF(3).Et(2)O gave only moderate yields (25-60%) of arsonolipids.
Collapse
|
18
|
Arsonoliposomes for the Potential Treatment of Medulloblastoma. Pharm Res 2009; 26:2237-46. [DOI: 10.1007/s11095-009-9940-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 07/06/2009] [Indexed: 10/20/2022]
|
19
|
Zagana P, Haikou M, Giannopoulou E, Ioannou PV, Antimisiaris SG. Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study. Mol Nutr Food Res 2009; 53:592-9. [DOI: 10.1002/mnfr.200700474] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
20
|
Piperoudi S, Ioannou PV, Frederik P, Antimisiaris SG. Arsonoliposomes: Effect of Lipid Composition on Their Stability and Morphology. J Liposome Res 2008; 15:187-97. [PMID: 16393910 DOI: 10.1080/08982100500364263] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The influence of the lipid composition of arsonoliposomes on their membrane integrity was investigated to evaluate whether it is possible to combine their action with drugs that can be encapsulated in their aqueous interior. This was investigated by measuring the retention of vesicle-encapsulated calcein (100 mM) during incubation, in the absence and presence of serum proteins. Liposomes containing various concentrations of arsonolipid (with the palmitoyl side chain) as well as egg-lecithin (phosphatidylcholine, PC) and cholesterol (lipid/chol 2:1 mol:mol) were prepared. In some experiments, PC was replaced by the synthetic phospholipid DSPC. All PC/arsonoliposomes tested are stable after 24 h of incubation in buffer at 37 degrees C. After incubation in the presence of serum proteins, arsonoliposomes that contain low amounts of arsonolipid (up to 5 mol% of the lipid content without cholesterol) are stable, whereas increased release of calcein is observed when vesicle arsonolipid concentration is raised (from 5 to 15 mol%). Further increase of arsonolipid content results in immediate decrease of calcein latency while the remaining calcein is rapidly released during incubation. DSPC/arsonoliposomes are comparably more stable, and membrane integrity is independent of the vesicle arsonolipid content, in the range investigated (15-40 mol% of the lipid content without cholesterol). Thereby, we conclude that more stable arsonoliposomes that incorporate high arsonolipid concentrations may be produced when PC is replaced by DSPC. The latter arsonoliposomes provide a system that may be used for combining arsonolipid activity with the activity of other drugs.
Collapse
Affiliation(s)
- Sophia Piperoudi
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Patras, Greece
| | | | | | | |
Collapse
|
21
|
A reinvestigation of the synthesis of arsonolipids (2,3-diacyloxypropylarsonic acids). Chem Phys Lipids 2008; 152:113-21. [DOI: 10.1016/j.chemphyslip.2008.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2007] [Revised: 02/04/2008] [Accepted: 02/04/2008] [Indexed: 11/16/2022]
|
22
|
Zagana P, Haikou M, Klepetsanis P, Giannopoulou E, Ioannou PV, Antimisiaris SG. In vivo distribution of arsonoliposomes: Effect of vesicle lipid composition. Int J Pharm 2008; 347:86-92. [PMID: 17689900 DOI: 10.1016/j.ijpharm.2007.06.048] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2007] [Revised: 06/21/2007] [Accepted: 06/27/2007] [Indexed: 11/16/2022]
Abstract
Sonicated arsonoliposomes were prepared using arsonolipid with palmitic acid acyl chain (C16), mixed with 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC-based), and cholesterol (Chol) with a molar ratio C16/DSPC/Chol 8:12:10. PEG-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) containing vesicles (Pegylated-arsonoliposomes) were also prepared. DSPC-based and Pegylated-arsonoliposomes, were administered by intraperitoneal injection in balb/c mice (15 mg arsenic/kg) and the distribution of As in the organs was measured by atomic absorption spectroscopy. Results demonstrate that a high portion of the dose administered is rapidly excreted since 1 h post-injection only about 30-40% of the dose was detected cumulatively in animal tissues. After this, the whole body elimination of arsenic was a slow process with a half-life of 27.6 h for Pegylated-arsonoliposomes, and 83 h, for the DSPC-based ones. For both arsonoliposomes, arsenic distribution was greater in intestines, followed by liver, carcass+skin stomach, spleen, kidney, lung and heart. Different arsenic kinetics in blood between the two liposome types were observed. Compared to the results obtained previously with PC-based arsonoliposomes, both the DSPC-based and Pegylated-arsonoliposomes have better bioavailability. This proves that arsonoliposome lipid composition (and consequently their integrity) influences their pharmacokinetic profile. Thus, the proper arsonoliposome composition should be used according to the intended application.
Collapse
Affiliation(s)
- Paraskevi Zagana
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, 26500 Rio, Greece
| | | | | | | | | | | |
Collapse
|
23
|
Lala MA, Tsivgoulis GM, Ioannou PV. Preparation of 2,3,4-Trihydroxybutylarsonic Acid: A Starting Compound for Novel Arsonolipids. PHOSPHORUS SULFUR 2007. [DOI: 10.1080/10426500701506184] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Maria A. Lala
- a Department of Chemistry , University of Patras , Patras, Greece
| | | | | |
Collapse
|
24
|
Zagana P, Klepetsanis P, Ioannou PV, Loiseau PM, Antimisiaris SG. Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition. Biomed Pharmacother 2007; 61:499-504. [PMID: 17606357 DOI: 10.1016/j.biopha.2007.05.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2007] [Accepted: 05/15/2007] [Indexed: 11/20/2022] Open
Abstract
Sonicated arsonoliposomes were prepared using an arsonolipid with palmitic acid acyl chain (C16), mixed with phosphatidylcholine (PC-based) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC-based), and cholesterol (Chol) with a molar ratio C16 /PC or DSPC/ Chol 8:12:10. PEG-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) containing vesicles (pegylated-arsonoliposomes) were also prepared. The in vitro and in vivo trypanocidal activity of the various types of arsonoliposomes was evaluated. Although PC-based arsonoliposomes exhibited in vivo activity on an acute trypanosomiasis animal model, no evidence of activity was demonstrated for DSPC-based or pegylated-arsonoliposomes on a chronic model. Despite the fact that DSPC-based and pegylated-arsonoliposomes have better bioavailability compared to PC-based ones, their in vitro activity is lower than that of PC-based arsonoliposomes, indicating the importance of arsonoliposome lipid composition on their trypanocidal activity and suggesting that further arsonoliposome structure design is required to overcome these disadvantages.
Collapse
Affiliation(s)
- Paraskevi Zagana
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio 26500, Greece
| | | | | | | | | |
Collapse
|
25
|
Tsivgoulis GM, Lala MA, Ioannou PV. Preparation of dl-2,3,4-trihydroxybutylarsonic acid and dl-2,3-dihydroxybutane-1,4-bis(arsonic acid): starting compounds for novel arsonolipids. Chem Phys Lipids 2007; 148:97-104. [PMID: 17555735 DOI: 10.1016/j.chemphyslip.2007.04.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2007] [Revised: 04/24/2007] [Accepted: 04/26/2007] [Indexed: 11/20/2022]
Abstract
The reaction of DL-1,3-butadiene diepoxide and of DL-1,4-dibromo-2,3-butanediol with aqueous alkaline sodium arsenite, "Na(3)AsO(3)", gave mixtures of the title arsonic acids which can be separated by anion exchange resin. Characterization of by-products leads to a better understanding of these reactions. These compounds are valuable intermediates for the preparation of novel arsonic acids and bis(arsonic acids).
Collapse
|
26
|
|
27
|
Koutsopoulos S, Fatouros DG, Ioannou PV, Antimisiaris SG. Thermal behavior of novel non-sonicated arsonolipid-containing liposomes. Biophys Chem 2006; 121:150-4. [PMID: 16472907 DOI: 10.1016/j.bpc.2006.01.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2005] [Revised: 01/13/2006] [Accepted: 01/13/2006] [Indexed: 11/18/2022]
Abstract
The thermal properties of novel arsonolipid-containing liposomes in PBS pH 7.4 and in water in absence and presence of Ca(2+) ions are reported. Liposomes composed of arsonolipids with different acyl chains (C(12), C(16) and C(18)) were prepared by the one step method. Microcalorimetry results showed that (i) the thermotropic transitions of arsonoliposomes (in PBS, pH 7.4, and in water) increase as a function of arsonolipid fatty acyl chain length, (ii) arsonoliposomes of long fatty acyl chain arsonolipids (C(16) and C(18)) showed higher enthalpy and transition temperature in the buffer compared to those observed in water (for arsonoliposomes of C(12)-fatty acyl chain arsonolipid, the order was reversed which might be attributed to their different structure), and (iii) the presence of 2 mM CaCl(2) has more pronounced effects on the thermal properties of arsonoliposomes in distilled water than in buffer, which suggests that the ionic strength of the dispersion medium plays an important role in determining the thermal properties of arsonoliposomes.
Collapse
Affiliation(s)
- Sotirios Koutsopoulos
- Center for Biomedical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, 02139-4307, USA
| | | | | | | |
Collapse
|
28
|
Piperoudi S, Fatouros D, Ioannou PV, Frederik P, Antimisiaris SG. Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles. Chem Phys Lipids 2006; 139:96-106. [PMID: 16405880 DOI: 10.1016/j.chemphyslip.2005.11.003] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2005] [Revised: 10/18/2005] [Accepted: 11/08/2005] [Indexed: 11/26/2022]
Abstract
We investigated the effect of pegylation on the physical stability, morphology and membrane integrity of arsonoliposomes. Arsonoliposomes composed of distearoylglycerophosphocholine (DSPC), cholesterol (Chol) and the palmitoyl side chain arsonolipid (with concentrations ranging from 0 mol% [DSPC/Chol vesicles] to 53 mol% of total lipid) containing either 4 or 8 mol% DPPE-PEG2000 or DSPE-PEG2000, were prepared by sonication. Arsonoliposome membrane integrity was evaluated by measuring the retention of encapsulated calcein in vesicles (during incubation in buffer or fetal calf serum [FCS]) while physical stability was evaluated by measuring vesicle dispersion turbidity (during incubation in water or CaCl(2)). Vesicle morphology was studied by cryo-electron microscopy. Experimental results show that: (i) PEG-lipids are incorporated in arsonoliposomes (as confirmed by the vesicle zeta potential modulation), (ii) pegylation of arsonoliposomes prevents their aggregation and fusion in the presence of calcium ions and (iii) when 8 mol% of PEG-DSPE is incorporated in arsonoliposomes based on their arsonolipid content, two groups of pegylated vesicles are formed: low content arsonoliposomes (<20 mol% arsonolipid) which are highly leaky and high content arsonoliposomes (>27 mol% arsonolipid) which are highly stable (70% calcein retention after 24h incubation in fetal calf serum [FCS]). In addition to high membrane integrity, the high content pegylated arsonoliposomes are morphologically perfect round-shaped vesicles without the sharp edges typically observed with non-pegylated DSPC-containing arsonoliposomes.
Collapse
Affiliation(s)
- Sophia Piperoudi
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, Rio 26500, Patras, Greece
| | | | | | | | | |
Collapse
|
29
|
Kallinteri P, Higgins S, Hutcheon GA, St Pourçain CB, Garnett MC. Novel functionalized biodegradable polymers for nanoparticle drug delivery systems. Biomacromolecules 2005; 6:1885-94. [PMID: 16004425 DOI: 10.1021/bm049200j] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We have prepared and screened a library of novel functionalized polymers for development of nanoparticle drug delivery systems. The polymer backbone consisting of two ester-linked, nontoxic, biological monomers, glycerol and adipic acid, was prepared using a hydrolytic enzyme. The specificity of the chosen enzyme yields a linear polymer with one free pendant hydroxyl group per repeat unit, which can be further functionalized. This protocol gives control over the backbone polymer molecular weight, together with the ability to incorporate various amounts of different fatty acyl substituents. These functionalized polymers are able to self-assemble into well-defined small particles of high homogeneity with a very low toxicity. They are able to incorporate a water soluble drug, dexamethasone phosphate, with a high efficiency and drug loading which varies with the polymer specification. The above characteristics strongly suggest that these polymers could be developed into useful nanoparticulate drug delivery systems.
Collapse
Affiliation(s)
- Paraskevi Kallinteri
- School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD United Kingdom
| | | | | | | | | |
Collapse
|
30
|
Fatouros DG, Piperoudi S, Gortzi O, Ioannou PV, Frederik P, Antimisiaris SG. Physical Stability of Sonicated Arsonoliposomes: Effect of Calcium Ions. J Pharm Sci 2005; 94:46-55. [PMID: 15761929 DOI: 10.1002/jps.20221] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The physical stability of sonicated arsonoliposomes in the absence and presence of Ca(2+) ions is evaluated. Cholesterol-containing arsonoliposomes composed of arsonolipids [having different acyl chains (C(12)-C(18))], or mixtures of arsonolipids with phospholipids (phosphatidylcholine or distearoyl-phosphatidylcholine) were prepared, and physical stability was evaluated in the absence and presence of CaCl(2), by vesicle dispersions turbidity measurements and cryo-electron microscopy morphological assessment. In some cases, vesicle zeta-potential was measured, under identical conditions. Results demonstrate that self-aggregation of the vesicles studied is low and influenced by the acyl chain length of the arsonolipid used, whereas calcium-induced aggregation is higher, correlating well with the decreased values of vesicle zeta-potential in the presence of Ca(2+) ions (weaker electrostatic repulsion). Acyl chain length of arsonolipids used has a significant quantitative effect on Ca(2+)-induced vesicle aggregation mainly for arsonoliposomes that contain phospholipids (mixed), compared with the vesicles that consist of plain arsonolipids (significant effect only for initial aggregation at time 0). Another difference between plain and mixed arsonoliposomes is that for mixed arsonoliposomes Ca(2+)-induced increases in turbidity are irreversible by ethylenediaminotetraacetic acid, suggesting that vesicle fusion is taking place. This was confirmed by cryo-electron microscopy observations. Finally, when phosphatidylcholine is replaced by distearoyl-phosphatidylcholine, arsonoliposomes are more stable in terms of self-aggregation, but in the presence of calcium, the turbidity and morphology results are similar.
Collapse
Affiliation(s)
- D G Fatouros
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26500 Patras, Greece
| | | | | | | | | | | |
Collapse
|
31
|
Zhou J, Zeng F, Xiang G, Xie S, Wei S. Preparation of arsenic trioxide albumin microspheres and its release characteristics in vitro. Curr Med Sci 2005; 25:310-2, 319. [PMID: 16201281 DOI: 10.1007/bf02828152] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2005] [Indexed: 10/19/2022]
Abstract
Arsenic trioxide albumin microspheres (As2O3-BSA-NS) were prepared by using methods of chemical cross-linking. The desirability function (DF), calculated according to the size (<1 microm) distribution, drug loading and drug trapping efficiency, was introduced as a total index for the microspheres formulation. Four factors, inculding W/O ratio, decentralization speed, BSA concentration and stirring stabilization time, were selected and arranged in an orthogonal experimental table. The release characteristic was studied by the drug release experiment in vitro. The four factors affected DF differently. Decentralization speed behaved as the maximum (P<0.01), followed by BSA concentration (P<0.05) and the W/O ratio dose (P<0.05). Stirring stabilization time did not influence DF (P>0.05). The release experiment in vitro showed that As2O3 in As2O3-BSA-NS was released more slower than pure As2O3. It was concluded that regular As2O3-BSA-NS may be prepared by the methods of chemical cross-linking, which was optimized by orthogonal experimental analysis of different factors, and the microspheres can release As2O3 slowly.
Collapse
Affiliation(s)
- Jie Zhou
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science, and Technology, Wuhan 430022, China
| | | | | | | | | |
Collapse
|
32
|
Antimisiaris SG, Klepetsanis P, Zachariou V, Giannopoulou E, Ioannou PV. In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. Int J Pharm 2004; 289:151-8. [PMID: 15652207 DOI: 10.1016/j.ijpharm.2004.11.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2004] [Revised: 10/07/2004] [Accepted: 11/05/2004] [Indexed: 11/26/2022]
Abstract
We recently showed that arsonoliposomes (novel arsenic containg liposomes) demonstrate differential toxicity towards various types of cancer and normal cells, in cell culture studies, as well as anti-parasitic activity. In this study, the in-vivo distribution of the active moiety of these vesicles, As, is evaluated. Sonicated arsonoliposomes were prepared using the arsonolipid with palmitic acid acyl chain (C16) mixed with egg-phosphatidyl choline (PC) and cholesterol (Chol) [C16/PC/Chol at 8:12:10 mol/mol/mol]. A dose of arsonoliposomes, corresponding to 5 mg arsenate/kg was administered by intraperitoneal injection in balb-c mice. At various time points post-injection the mice were sacrificed and the distribution of As in the organs was measured, by atomic absorption spectroscopy. Results demonstrate that a high portion of the dose administered is rapidly excreted; since 1-h post-injection only about 30% of the dose administered was detected cumulatively in the animal tissues. After this the elimination of arsenic was a slow process with a total body elimination rate constant of 0.023 h(-1), corresponding to a half-life of 30 h. Tissues with the highest arsenic concentration during the study period are: spleen-kidneys-stomach, followed by lung, liver, intestines-heart, carcass+skin and finally blood. No acute toxicity, or effect on the body or organ weight of the mice was observed.
Collapse
|
33
|
Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res 2004; 14:27-38. [PMID: 15461930 DOI: 10.1081/lpr-120039661] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The use of arsenic-containing compounds in cancer therapy is currently being re-considered, after the recent approval of arsenic trioxide (Trisenox) for the treatment of relapsed promyelocytic leukemia (PML). In an attempt to prepare a carrier system to minimize the toxicity of this drug, the aim of this study is to prepare and characterize liposomes encapsulating arsenic trioxide (ATO). For this, we prepared different types of liposomes entrapping ATO: large multilamellar (MLV), sonicated (SUV) and dried reconstituted vesicles (DRV). The techniques used were: thin film hydration, sonication and the DRV method, respectively. Two lipid compositions were studied for each liposome type, EggPC/Chol (1:1) and DSPC/Chol (1:1). After liposome preparation, drug encapsulation was evaluated by measuring arsenic in liposomes. For this, energy-dispersive X-ray fluorescence spectroscopy or atomic absorption was used. In addition, the retention of the drug in the liposomes was evaluated after incubating the liposomes in buffer at 37 degrees C. The experimental results reveal that encapsulation of ATO in liposomes ranges between 0.003 and 0.506 mol/ mol of lipid, and is highest in the DRV vesicles and lowest in the small unilamellar vesicles, as anticipated. Considering the in vitro stability of ATO-encapsulating liposomes: 1) For the PC/Chol liposomes (DRV and MLV), after 24 hours of incubation, more than 70% (or 90% in some cases) of the initially encapsulated amount of ATO was released. 2) The liposomes composed of DSPC/Chol could retain substantially higher amounts of ATO, especially the DRV liposomes (54% retained after 24 h). 3) In the case of PC/Chol, temperature of incubation has no effect on the ATO release after 24 hours, but affects the rate of ATO release in the MLV liposomes, while for the DSPC/Chol liposomes there is a slight increase (statistically insignificant) of ATO release at higher temperature.
Collapse
Affiliation(s)
- Paraskevi Kallinteri
- Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, Rio, Greece
| | | | | | | |
Collapse
|
34
|
Abstract
Natural arsenolipids are analogues of neutral lipids, like monoglycerides, glycolipids, phospho- and also phosphonolipids. They have been found in microorganisms, fungi, plants, lichens, in marine mollusks, sponges, other invertebrates, and in fish tissues. This review presented structures of natural arsenolipids (and derivatives), their distribution, biogenesis in algae and invertebrates, synthesis, and also biological activity. Arsenolipids are thought to be end products of arsenate detoxification processes, involving reduction and oxidative methylation and adenosylation. The proposed biogenesis of arsenolipids is based on the natural occurrence of arsenic metabolites, and all the intermediates in the proposed pathway have been identified as natural products of algal origin. Different arseno species are shown to be inhibitors of glycerol kinase, bovine carbonic anhydrase, and also is an effective therapy for acute promyelocytic leukemia, and there has been promising activity noted in other hematologic and solid tumors. Arsonoliposomes demonstrated high anti-trypanosomal activity against Trypanosoma brucei and inhibit growth of some types of cancer cells (HL-60,C6 and GH3).
Collapse
Affiliation(s)
- Valery M Dembitsky
- Department of Organic Chemistry, P.O. Box 39231, Hebrew University, Jerusalem 91391, Israel.
| | | |
Collapse
|
35
|
Antimisiaris SG, Ioannou PV, Loiseau PM. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. J Pharm Pharmacol 2003; 55:647-52. [PMID: 12831507 DOI: 10.1211/002235703765344559] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
We have studied the antiprotozoal activity of some recently prepared and characterized arsonoliposome formulations. Plain arsonoliposomes and phosphatidylcholine arsonoliposomes prepared with palmitoyl- (C16) or lauroyl-(C12) acyl side chain arsonolipids showed in-vitro antileishmanial activity after a 72-h incubation period against wild-type promastigote forms of Leishmania donovani. The IC50 values ranged from 0.40 to 11.6 microM arsonolipid. Interestingly, all preparations tested were found to be significantly more potent against amphotericin B- or miltefosine-resistant promastigote forms of L. donovani, with IC50 values ranging between 0.21- and 2.33 microM arsonolipid. When tested in-vitro against Trypanosoma brucei brucei, all arsonoliposome formulations were found to have anti-trypanosomal activity after a 24-h incubation period. The fact that the corresponding arsonolipids (dissolved in dimethyl sulfoxide) were found not to be potent against the Leishmania promastigotes or the trypanosomes tested suggested that the formation of liposomes possibly influenced the mode of interaction between the active lipid and the parasites modulating their potency. In addition, a preliminary in-vivo study in BALB/c mice was performed for the initial evaluation of the biodistribution of arsonoliposomes. The accumulation of arsenic in the BALB/c mouse liver in relatively high amounts was an additional advantage of this approach for anti-protozoal therapy, especially for visceral leishmaniasis where parasites are located mainly in the liver.
Collapse
Affiliation(s)
- Sophia G Antimisiaris
- Department of Pharmacy, Laboratory of Pharmaceutical Technology, University of Patras, Rio 26500, Greece.
| | | | | |
Collapse
|
36
|
Gortzi O, Antimisiaris SG, Klepetsanis P, Papadimitriou E, Ioannou PV. Arsonoliposomes: effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture. Eur J Pharm Sci 2003; 18:175-83. [PMID: 12594011 DOI: 10.1016/s0928-0987(02)00259-2] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Arsonolipid-containing liposomes were investigated in order to characterize the influence of the lipid acyl-chain length and liposome composition on cytotoxicity. Three types of cancer cells (HL-60, C6 and GH3), and two types of normal cells (HUVEC and RAME) were used. Liposomes containing the lauroyl, myristoyl and stearoyl side chain arsonolipids (with different lipid compositions) were incubated with a given number of cells and cell viability was estimated (MTT assay and trypan blue exclusion). Morphological studies were also performed in some cases. In addition, the interaction between some of the prepared arsonoliposomes and HUVEC cells was assessed. Results reveal that all the studied arsonoliposomes cause a dose dependent inhibition of survival in all three malignant cell lines studied (initiated at 10(-6) M). The corresponding toxicity against normal cells (HUVEC and RAME) is much lower for all arsonoliposomes, except for the lauroyl side chain arsonoliposomes which were demonstrated to be relatively toxic towards normal cells, especially RAME. The microscopic observations that these vesicles possibly cause apoptosis of most cell types studied, as well as the different speed of their cytotoxic activity, imply a different mechanism of action for this arsonoliposome type. Taking the results of this study in conjunction with our previous results on arsonoliposome physical stability and cytotoxicity, it is recommended that palmitoyl-arsonolipid arsonoliposomes be used for further investigations in vivo towards the development of an anticancer product.
Collapse
Affiliation(s)
- Olga Gortzi
- Department of Pharmacy, University of Patras, Rio 26500, Patras, Greece
| | | | | | | | | |
Collapse
|
37
|
Terzis A, Ioannou PV. Preparation of pseudo-arsonolipids: 2-acyloxypropane-1,3-bis(arsonic acids). The crystal structure of 2-hydroxypropane-1,3-bis(arsonic acid). Chem Phys Lipids 2002; 117:53-61. [PMID: 12191844 DOI: 10.1016/s0009-3084(02)00030-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Epihalohydrins react with alkaline arsenite to give in very good yields 2-hydroxypropane-1,3-bis(arsonic acid) (7), a key compound for the synthesis of pseudo-arsonolipids and more complex arsinolipids. Through a series of reduction to -As(SPh)(2), acylation, and oxidation to -AsO(3)H(2), pseudo-arsonolipids, i.e. 2-acyloxypropane-1,3-bis(arsonic acids), were obtained. These pseudo-lipids are very sensitive to bases, being de-acylated. The bis(arsonic acid) (7) crystallizes in the orthorombic space group P2(1)2(1)2(1) with unit cell constants a=6.911(3), b=17.496(8), c=7.002(3) A. Both arsenic atoms are essentially tetrahedral being bound to three oxygens and one carbon. All hydrogen atoms have been located. There is no intramolecular but only intermolecular hydrogen bonding involving all the As=O, As-OH, and C-OH groups. The C-OH group acts as a hydrogen donor to an acidic As-OH, and this As-OH, in turn, acts as a hydrogen donor to an As=O group.
Collapse
Affiliation(s)
- Aris Terzis
- Institute of Material Science, NCSR Democritos, 15310 Aghia Paraskevi Attikis, Greece.
| | | |
Collapse
|
38
|
Ioannou PV. Synthesis of arsinolipids. II. A non-isosteric analogue of fully acylated cardiolipin. Chem Phys Lipids 2002; 117:7-18. [PMID: 12191840 DOI: 10.1016/s0009-3084(02)00009-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
2-Hydroxypropane-1,3-bis(arsonic acid) after six successive reactions gives the arsinolipid 2-acyloxy-As, As'-bis[2,3-di(acyloxy)propyl]propane-1,3-diylbis(arsinic acid) in 20-40% overall yields. This arsinolipid is a non-isosteric analogue of the fully acylated cardiolipin. The R- and S-glycidol, used to create the backbone of the lipid, give the optically active RR and SS, respectively, arsinolipids, while the rac-glycidol produces a mixture of diastereomers (a racemic pair, RR and SS, and two meso forms with an RS configuration). Some properties of these arsinolipids are described, from which the most interesting are the facile hydrolysis of the middle acyl group and their tendency to absorb environmental water.
Collapse
|